V
Virginia Valeria Ferretti
Researcher at University of Pavia
Publications - 112
Citations - 5352
Virginia Valeria Ferretti is an academic researcher from University of Pavia. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 25, co-authored 89 publications receiving 4380 citations.
Papers
More filters
Journal ArticleDOI
Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
Thorsten Klampfl,Heinz Gisslinger,Ashot S. Harutyunyan,Harini Nivarthi,Elisa Rumi,Jelena D. Milosevic,Nicole C.C. Them,Tiina Berg,Bettina Gisslinger,Daniela Pietra,Doris Chen,Gregory I. Vladimer,Klaudia Bagienski,Chiara Milanesi,Ilaria Carola Casetti,Emanuela Sant'Antonio,Virginia Valeria Ferretti,Chiara Elena,Fiorella Schischlik,Ciara Cleary,Melanie Six,Martin Schalling,Andreas Schönegger,Christoph Bock,Luca Malcovati,Cristiana Pascutto,Giulio Superti-Furga,Mario Cazzola,Robert Kralovics +28 more
TL;DR: Most patients with essential thrombocythemia or primary myelofibrosis that was not associated with a JAK2 or MPL alteration carried a somatic mutation in CALR, and patients with mutated CALR had a lower risk ofThrombosis and longer overall survival than patients with mutations in J AK2.
Journal ArticleDOI
JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes
Elisa Rumi,Daniela Pietra,Virginia Valeria Ferretti,Thorsten Klampfl,Ashot S. Harutyunyan,Jelena D. Milosevic,Nicole C.C. Them,Tiina Berg,Chiara Elena,Ilaria Carola Casetti,Chiara Milanesi,Emanuela Sant'Antonio,Marta Bellini,Elena Fugazza,Maria C. Renna,Emanuela Boveri,Cesare Astori,Cristiana Pascutto,Robert Kralovics,Robert Kralovics,Mario Cazzola +20 more
TL;DR: Observations are consistent with the notion that JAK2-mutated essential thrombocythemia and polycythemia vera represent different phenotypes of a single myeloproliferative neoplasm, whereas CALR-mutation essential thROMbocyhimia is a distinct disease entity.
Journal ArticleDOI
Clinical significance of somatic mutation in unexplained blood cytopenia
Luca Malcovati,Anna Gallì,Erica Travaglino,Ilaria Ambaglio,Ettore Rizzo,Elisabetta Molteni,Chiara Elena,Virginia Valeria Ferretti,Silvia Catricalà,Elisa Bono,Gabriele Todisco,Antonio Bianchessi,Elisa Rumi,Silvia Zibellini,Daniela Pietra,Emanuela Boveri,Clara Camaschella,Daniela Toniolo,Elli Papaemmanuil,Seishi Ogawa,Mario Cazzola +20 more
TL;DR: Mutation analysis on peripheral blood granulocytes may significantly improve the current diagnostic approach to unexplained cytopenia and more generally the diagnostic accuracy of myeloid neoplasms.
Journal ArticleDOI
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis
Elisa Rumi,Daniela Pietra,Cristiana Pascutto,Paola Guglielmelli,Alejandra Martínez-Trillos,Ilaria Carola Casetti,Dolors Colomer,Lisa Pieri,Marta Pratcorona,Giada Rotunno,Emanuela Sant'Antonio,Marta Bellini,Chiara Cavalloni,Carmela Mannarelli,Chiara Milanesi,Emanuela Boveri,Virginia Valeria Ferretti,Cesare Astori,Vittorio Rosti,Francisco Cervantes,Giovanni Barosi,Alessandro M. Vannucchi,Mario Cazzola +22 more
TL;DR: Observations indicate that driver mutations define distinct disease entities within PMF, which is not only relevant to clinical decision-making, but should also be considered in designing clinical trials.
Journal ArticleDOI
Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms
Daniela Pietra,Elisa Rumi,Virginia Valeria Ferretti,C. A. Di Buduo,Chiara Milanesi,Chiara Cavalloni,Emanuela Sant'Antonio,Vittorio Abbonante,Francesco Moccia,Ilaria Carola Casetti,Marta Bellini,Maria C. Renna,Elisa Roncoroni,Elena Fugazza,Cesare Astori,Emanuela Boveri,Vittorio Rosti,G Barosi,Alessandra Balduini,Alessandra Balduini,Mario Cazzola +20 more
TL;DR: Mutation subtype contributes to determining clinical phenotype and outcomes in CALR-mutant myeloproliferative neoplasms, and CALR variants that markedly impair the calcium binding activity of mutant calreticulin are mainly associated with a myelofibrosis phenotype.